Lipoprotein-associated phospholipase A2 activity in patients with preserved left ventricular ejection fraction

Abstract

Confirming its role as a marker of vascular inflammation, LpPLA2 seems to be a biomarker constantly correlated with HF, regardless of etiology. Elevated plasma values of LpPLA2 in HFpEF are consistent with the exacerbated inflammatory status.

Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein‐Associated Phospholipase A2 Activity: A Cross‐Sectional Study

“…Even though plasma Lp‐PLA 2 activity appears to be increased in inflammation‐related states, such as subclinical atherosclerosis, heart failure, and type 2 diabetes mellitus (T2DM) (Garg et al, ; Liu et al, ; Moldoveanu et al, ), the association of Lp‐PLA 2 activity with inflammatory markers is inconclusive as far as it concerns general population without CVD (Chae et al, ; Paik et al, ). Additionally, the association of Lp‐PLA 2 activity with adiponectin is either insignificant in men and women without incident CHD in a nested case–control study among participants of the EPIC‐Norfolk cohort, or is negative in obese adolescents with and without T2DM (Rana et al, ; Seyfarth et al, ).…”

Lipoprotein-associated phospholipase A2 predicted cardiovascular disease in obstructive sleep apnea syndrome

“…These mediators triggered the inflammatory cascade, induced the chemotaxis of leucocytes into the sub-intimal space of the arterial wall and converted them into foam cells. As a consequence, Lp-PLA2 enhanced the growth and the instability of the lipid core of the atherosclerotic plaques, which consequently led to acute cardiovascular events [27][28][29]. Several studies have confirmed the roles of Lp-PLA2 as a predictor of CVD morbidity and mortality in apparently healthy populations, in diabetic and dysmetabolic patients and those with cardiac disease [30,31].…”

Lipoprotein-Associated Phospholipase A2 – Pathophysiological Role and Clinical Significance as a Cardiovascular Biomarker

“…Lp-PLA 2 was strongly and independently associated with mortality in patients under 80 years of age. Moldoveanu et al's study [64] in 208 patients with HF found significantly increased Lp-PLA 2 activity in HF patients with preserved ejection fraction (EF) than in HF with reduced EF. The literature data about the association of Lp-PLA 2 and heart failure on admission in patients with acute myocardial infarction are missing.…”

“…A dissociation could be noted between mass and activity in terms of risk prediction. Several of the epidemiology studies have measured only Lp-PLA 2 mass (26,30,33,44,47,57,63,65,69), whereas others measured only enzyme activity (31,50,62,64,67) and a few have measured both in the same study population (25,27,28,76). Recently published meta-analysis assessed the 32 prospective studies of Lp-PLA 2 and cardiovascular outcomes.…”